Robert McWhirter
Member since: Nov '00
President at
Selective Asset Management

Latest Top Picks

(A Top Pick Aug 01/19, Down 25%) People are concerned about construction levels, but ARE will do okay. He stopped out.
(A Top Pick Aug 01/19, Up 24%) There's been a lot going here: the reported good phase 2 drug test results. They did financing recently and are planning for phase 3 which will cost $50 million, so they have enough cash for 18 months. The next phase will start in Q2 2021 and last two years. Generally, drugs that pass phase 2 have a good outlook entering phase 3. ATE continues to talk to third parties about mass-producing the drug.
(A Top Pick Aug 01/19, Down 40%) BAD is associated with shale oil, which of course hasn't done well. But BAD has a mobile fleet that can perform other work. There are better stocks elsewhere, including gold.
The operate gold and copper mines in Bulgaria and Namibia. Earnings up 80% YOY, and boast a 9.2% free cash flow yield. Cash flow to grow 74% in 2020 and 17% in 2021. Price-to-cash flow is 5.9x. ROE expected this year is 21%. (Analysts’ price target is $9.23)
Pays a 1.5% yield. 13% YOY sales growth and a large 12.8% free cash flow yield. Cash flow grew YOY 236%. Earnings to grow 7% this year and 5% in 2021 with a PE of 14.3x. (Analysts’ price target is $37.67)